LexDanaLexDanabeta
Inventor

Michael P. Dwyer

Inventor
Scotch Plains, NJ, US

Overview

51→
Patents
2005–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 51 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations39%
C07DHeterocyclic compounds38%
A61KPreparations for medical, dental or toiletry purposes18%
C07CAcyclic or carbocyclic compounds2%
Y02PClimate change mitigation technologies in the production or processing of goods2%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
10,646,494Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases202010,357,481Substituted triazolo bicyclic compounds as PDE2 inhibitors201910,287,293Bicyclic heterocyclic compounds as PDE2 inhibitors201910,174,037Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors201910,160,7626-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors201810,138,255Piperazine derivatives as HIV protease inhibitors20189,840,478'Piperazine derivatives as HIV protease inhibitors'20179,254,292'Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases'20168,987,242'Morpholinone compounds as factor IXA inhibitors'20158,673,924'Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors'20148,642,582'Morpholinone compounds as factor IXa inhibitors'20148,609,676'4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors'20138,586,576'Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors'20138,580,782'Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors'20138,318,735'2-aminothiazole-4-carboxylic amides as protein kinase inhibitors'20128,211,854'Methods for inhibiting protein kinases'20128,207,221'Crystalline polymorphs of a CXC-chemokine receptor ligand'20127,964,646'3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands'20117,947,720'3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands'20117,807,683'N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors'20107,776,865'Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors'20107,645,762'Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors'20107,642,266'Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors'20107,605,155'Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors'20097,601,724'Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors'20097,576,085'Imidazopyrazines as cyclin dependent kinase inhibitors'20097,563,798'Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors'20097,514,442'Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors'20097,511,049'Pyrazolopyrimidines as cyclin dependent kinase inhibitors'20097,470,695'N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors'20087,468,372'Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors'20087,452,902'Imidazopyridines as cyclin dependent kinase inhibitors'20087,449,488'Pyrazolopyrimidines as protein kinase inhibitors'20087,432,265'Imidazopyrazines as cyclin dependent kinase inhibitors'20087,309,705'Pyrazolopyrimidines as cyclin dependent kinase inhibitors'20077,205,308'Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors'20077,196,078'Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors'20077,196,092'N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors'20077,186,740'Imidazopyrazines as cyclin dependent kinase inhibitors'20077,161,003'Pyrazolopyrimidines as cyclin dependent kinase inhibitors'20077,151,104'Pyrazolopyridines as cyclin dependent kinase inhibitors'20067,132,445'3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands'20067,119,200'Pyrazolopyrimidines as cyclin dependent kinase inhibitors'20067,084,271'Pyrazolopyrimidines as cyclin dependent kinase inhibitors'20067,078,525'Pyrazolopyrimidines as cyclin dependent kinase inhibitors'20067,074,924'Pyrazolopyrimidines as cyclin dependent kinase inhibitors'20067,067,661'Pyrazolopyrimidines as cyclin dependent kinase inhibitors'20066,992,080'Imidazopyridines as cyclin dependent kinase inhibitors'20066,919,341'Imidazopyrazines as cyclin dependent kinase inhibitors'20056,903,131'3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists'20056,878,709'3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists'2005

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2005–2012Patents assigned to SCHERING CORP (27)· patent assignee history
2005–2011Patents assigned to PHARMACOPEIA DRUG DISCOVERY (11)· patent assignee history
2005–2020Based in Scotch Plains, NJ, US· patent location history
2012–2020Patents assigned to MERCK SHARP & DOHME (15)· patent assignee history
2012–2019Patents assigned to DWYER MICHAEL P (9)· patent assignee history
2012–2014Patents assigned to GUZI TIMOTHY J (5)· patent assignee history
2019Based in Rahway, NJ, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
SCHERING CORP272005–2012
MERCK SHARP & DOHME152012–2020
PHARMACOPEIA DRUG DISCOVERY112005–2011
DWYER MICHAEL Pself92012–2019
GUZI TIMOTHY J52012–2014
Locations
LocationPatentsSpan
Scotch Plains, New Jersey, US502005–2020
Rahway, New Jersey, US12019